For patients with advanced lung adenocarcinoma and an EGFR mutation, treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the five-year survival rate is 40–50% [4,5]. The gene discussed is EGFR; the disease is lung adenocarcinoma.